899809-61-1 Usage
General Description
4-Hydroxy-N,N-diphenyl-(4R)-2-Pentynamide is a chemical compound with a complex molecular structure. Key traits of this chemical include its Hydroxy and amide functional groups, along with its structural inclusion of diphenyl and pentynamide chains. It is categorized as an organic compound, arising from the family of anilides and phenylpropanoids. The structure usually contains a hydroxy group (-OH) attached to a benzene ring and two phenyl groups (-C6H5) attached to the nitrogen of an amide group, besides a pentynyl group (-C2H3). The functionalities and applications of this chemical mostly depend on its chemical structure and behavior. However, detailed information about its specific properties, usages, hazards, and handling procedures are not widely available in public domains, indicating that they might be industry-specific or are less investigated.
Check Digit Verification of cas no
The CAS Registry Mumber 899809-61-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,9,9,8,0 and 9 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 899809-61:
(8*8)+(7*9)+(6*9)+(5*8)+(4*0)+(3*9)+(2*6)+(1*1)=261
261 % 10 = 1
So 899809-61-1 is a valid CAS Registry Number.
899809-61-1Relevant articles and documents
Thrombin Receptor Antagonists Based On The Modified Tricyclic Unit Of Himbacine
-
Page/Page column 29, (2008/06/13)
Multiple stereoisomers of the heterocyclic-substituted tricyclics of the formula: or a pharmaceutically acceptable salt, solvate, or ester of said compound wherein R and the stereochemistry are illustrated in the structural formulas herein are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
AN EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS
-
Page/Page column 27; 28, (2008/06/13)
This application discloses a novel process for the synthesis of himbacine analogs, as well as the compounds produced thereby. The synthesis proceeds by alternative routes including the cyclic ketal amide route, the chiral carbamate amide route, and the ch
